Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

5
results for

"Survival rate"

Article category

Keywords

Publication year

"Survival rate"

Original Articles

Hepatic neoplasm

Stereotactic body radiation therapy for small (≤5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial
Sang Min Yoon, So Yeon Kim, Young-Suk Lim, Kang Mo Kim, Ju Hyun Shim, Danbi Lee, Jihyun An, Jinhong Jung, Jong Hoon Kim, Han Chu Lee
Clin Mol Hepatol 2020;26(4):506-515.
Published online July 10, 2020
DOI: https://doi.org/10.3350/cmh.2020.0038
Background/Aims
Stereotactic body radiation therapy (SBRT) is used as an alternative ablative treatment in patients with hepatocellular carcinoma (HCC) not suitable for curative treatments. The purpose of this prospective study was to evaluate the long-term efficacy of SBRT for small (≤5 cm) HCCs.
Methods
A phase II, single-arm clinical trial on SBRT for small HCCs was conducted at an academic tertiary care center. The planned SBRT dose was 45 Gy with a fraction size of 15-Gy over 3 consecutive days. The primary endpoint was 2-year local control rate. Radiologic responses were assessed according to the Response Evaluation Criteria in Solid Tumors (RECIST, version 1.1) and the modified RECIST criteria.
Result
s: Between 2013 and 2016, 50 patients (53 lesions) were enrolled, with a median follow-up period of 47.8 months (range, 2.9–70.6). Patients’ age ranged from 41 to 74 years, and 80% were male. Median tumor size was 1.3 cm (range, 0.7–3.1). The 2- and 5-year local control rates were 100% and 97.1%, respectively. The 5-year overall survival rate was 77.6%. Six months after SBRT, radiologic responses were evident in 44 lesions (83%) according to the RECIST criteria and 49 (92.4%) according to the modified RECIST criteria. None of the patients showed grade ≥3 adverse events.
Conclusions
SBRT showed excellent results as an ablative treatment for patients with small HCCs while showing minimal toxicities. SBRT can be a good alternative for both curative and salvage intents in patients with HCCs that are unsuitable for curative treatments.

Citations

Citations to this article as recorded by  Crossref logo
  • α/β for Hepatocellular Carcinoma Tumors Treated with Radiation Therapy
    Lise Wei, Yaxuan Huang, Randall K. Ten Haken, Teodor Stanescu, Laura A. Dawson, Theodore S. Lawrence, Jeremy M.G. Taylor
    International Journal of Radiation Oncology*Biology*Physics.2026;[Epub]     CrossRef
  • Exploring the Evolving Landscape of Stereotactic Body Radiation Therapy in Hepatocellular Carcinoma
    Deepti Sharma, Divya Khosla, Babu L. Meena, Hanuman P. Yadav, Rakesh Kapoor
    Journal of Clinical and Experimental Hepatology.2025; 15(1): 102386.     CrossRef
  • Stereotactic body radiotherapy alone versus stereotactic body radiotherapy after incomplete transarterial therapy for hepatocellular carcinoma
    Youngju Song, Jinhong Jung, Jin‐hong Park, So Yeon Kim, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young‐Suk Lim, Han Chu Lee, Sang Min Yoon
    Journal of Medical Imaging and Radiation Oncology.2025; 69(1): 144.     CrossRef
  • Comparison of stereotactic body radiotherapy and transcatheter arterial chemoembolization for hepatocellular carcinoma: Systematic review and meta‐analysis
    Satoshi Komiyama, Atsuya Takeda, Yudai Tateishi, Yuichiro Tsurugai, Takahisa Eriguchi, Nobuyuki Horita
    Radiotherapy and Oncology.2025; 202: 110614.     CrossRef
  • Development and Validation of a Prediction Model for Cardiac Events in Patients With Hepatocellular Carcinoma Undergoing Stereotactic Body Radiation Therapy
    Hye In Lee, Jaeman Son, Byungchul Cho, Youngmoon Goh, Jinhong Jung, Jin-hong Park, Eui Kyu Chie, Kyung Su Kim, Young-Hak Kim, Hyun-Cheol Kang, Sang Min Yoon
    International Journal of Radiation Oncology*Biology*Physics.2025; 122(5): 1272.     CrossRef
  • Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
    Soo Young Hwang, Pojsakorn Danpanichkul, Vatche Agopian, Neil Mehta, Neehar D. Parikh, Ghassan K. Abou-Alfa, Amit G. Singal, Ju Dong Yang
    Clinical and Molecular Hepatology.2025; 31(Suppl): S228.     CrossRef
  • Proton beam therapy in the management of hepatocellular carcinoma
    Kenneth S. H. Chok, Tiffany Y. T. Joeng, Darren M. C. Poon
    Expert Review of Gastroenterology & Hepatology.2025; 19(5): 495.     CrossRef
  • Modern approach to hepatocellular carcinoma treatment
    Francesco Cortese, Fotis Anagnostopoulos, Maria Vittoria Bazzocchi, Silvio Caringi, Antonio Rosario Pisani, Matteo Renzulli, Ioannis Paraskevopoulos, Letizia Laera, Alessia Surgo, Stavros Spiliopoulos, Riccardo Memeo, Riccardo Inchingolo
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • Dynamic Tumor Tracking (DTT) for Hepatocellular Carcinoma Using the Vero4DRT Gimbaled Linac Stereotactic Body Radiation Therapy (SBRT) System
    Ronan L. McDermott, Emma M. Dunne, Lok In Josephine Ma, Alanah M Bergman, Marie-Laure A. Camborde, Tania Karan, Ante Mestrovic, Emilie E. Carpentier, Mitchell C. C. Liu, Devin Schellenberg, Roy M. K. Ma
    Cancers.2025; 17(17): 2926.     CrossRef
  • Stereotactic hepatic radiation therapy and immunotherapy in hepatocellular carcinoma
    Carmen Cañadillas Navero, Íñigo San Miguel Arregui, Luis Alberto Pérez Romasanta
    Revisiones en Cáncer.2025;[Epub]     CrossRef
  • China Liver Cancer Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2024 Edition)
    Jian Zhou, Huichuan Sun, Zheng Wang, Wenming Cong, Mengsu Zeng, Weiping Zhou, Lianxin Liu, Tianfu Wen, Ming Kuang, Bixiang Zhang, Kaishan Tao, Guohong Han, Zhiping Yan, Maoqiang Wang, Ruibao Liu, Jinhe Guo, Zhaochong Zeng, Ping Liang, Zhenggang Ren, Jinli
    Liver Cancer.2025; : 1.     CrossRef
  • The #HOPE4LIVER Single-arm Pivotal Trial for Histotripsy of Primary and Metastatic Liver Tumors
    Timothy J. Ziemlewicz, Jeffrey J. Critchfield, Mishal Mendiratta-Lala, Philipp Wiggermann, Maciej Pech, Xavier Serres-Créixams, Meghan Lubner, Tze Min Wah, Peter Littler, Clifford R. Davis, Govindarajan Narayanan, Sarah B. White, Osman Ahmed, Zach S. Coll
    Annals of Surgery.2025; 282(6): 908.     CrossRef
  • Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: Meta-Analysis and International Stereotactic Radiosurgery Society Practice Guidelines
    Sun Hyun Bae, Seok-Joo Chun, Joo-Hyun Chung, Eunji Kim, Jin-Kyu Kang, Won Il Jang, Ji Eun Moon, Isaure Roquette, Xavier Mirabel, Tomoki Kimura, Masayuki Ueno, Ting-Shi Su, Alison C. Tree, Matthias Guckenberger, Simon S. Lo, Marta Scorsetti, Ben J. Slotman
    International Journal of Radiation Oncology*Biology*Physics.2024; 118(2): 337.     CrossRef
  • Concurrent nivolumab and external beam radiation therapy for hepatocellular carcinoma with macrovascular invasion: A phase II study
    Bo Hyun Kim, Hee Chul Park, Tae Hyun Kim, Young-Hwan Koh, Jung Yong Hong, Yuri Cho, Dong Hyun Sinn, Boram Park, Joong-Won Park
    JHEP Reports.2024; 6(4): 100991.     CrossRef
  • Chemoembolization versus Radiotherapy for Single Hepatocellular Carcinomas of ≤3 cm Unsuitable for Image-Guided Tumor Ablation
    Jihye Lim, Euichang Kim, Sehee Kim, So Yeon Kim, Jin Hyoung Kim, Sang Min Yoon, Ju Hyun Shim
    Gut and Liver.2024; 18(1): 125.     CrossRef
  • Canine primary liver tumors treated with stereotactic body radiation therapy: A case series
    Qiao Ying Pauline Chan, Deanna Morrow, David Lurie
    Veterinary Radiology & Ultrasound.2024; 65(2): 121.     CrossRef
  • Optimal hypofractionated radiation therapy schemes for early-stage hepatocellular carcinoma
    Feng Liu, Doris R. Brown, Michael T. Munley
    Radiotherapy and Oncology.2024; 194: 110223.     CrossRef
  • Stereotactic body radiation therapy in patients with centrally located hepatocellular carcinoma: A retrospective, single-arm, multi-center study
    Dan-Xue Zheng, Yi-Xing Chen, Jing Sun, Yong Hu, Ping Yang, Yang Zhang, Xue-Zhang Duan, Zhao-Chong Zeng
    Clinical and Translational Radiation Oncology.2024; 46: 100767.     CrossRef
  • Dynamic liver volume change in predicting hepatic decompensation and long‐term effects of stereotactic body radiation therapy
    Sumin Lee, Jonggi Choi, Jin‐hong Park, Chae Yeon Lim, Eunyeong Yang, Sang Min Yoon, Jinhong Jung
    Journal of Gastroenterology and Hepatology.2024; 39(8): 1648.     CrossRef
  • Stereotactic body radiotherapy is an alternative to radiofrequency ablation for single HCC ≤5.0 cm
    Zhoutian Yang, Shiliang Liu, Li Hu, Jinbin Chen, Juncheng Wang, Yangxun Pan, Li Xu, Mengzhong Liu, Minshan Chen, Mian Xi, Yaojun Zhang
    JHEP Reports.2024; 6(10): 101151.     CrossRef
  • Clinical outcomes and safety of external beam radiotherapy with extensive intrahepatic targets for advanced hepatocellular carcinoma: A single institutional clinical experience
    Sunmin Park, Chai Hong Rim, Won Sup Yoon
    Saudi Journal of Gastroenterology.2024; 30(6): 399.     CrossRef
  • Long-term outcomes of more than a decade treating patients with stereotactic body radiation therapy for hepatocellular carcinoma
    Wilhelm den Toom, Eva M. Negenman, Francois E.J.A. Willemssen, Erik van Werkhoven, Robert J. Porte, Roeland F. de Wilde, Dave Sprengers, Imogeen E. Antonisse, Ben J.M. Heijmen, Alejandra Méndez Romero
    Clinical and Translational Radiation Oncology.2024; 49: 100878.     CrossRef
  • Long-Term Outcome of a Multicenter Prospective Study on Efficacy and Safety of High-Dose Stereotactic Body Radiation Therapy ≥48-h Interfraction Interval for ≤5 cm Hepatocellular Carcinoma
    Jin-Kyu Kang, Mi-Sook Kim, Won Il Jang, Chul Ju Han, Jin Kim, Su Cheol Park, Young-Joo Shin, Chul Won Choi, Wan Jeon, Tosol Yu, Ah Ram Chang, Hae Jin Park, Younghee Park, Eun Seog Kim, Sunmi Jo, Woo Chul Kim, Hun Jung Kim, Sun Hyun Bae, Eunji Kim
    Liver Cancer.2024; 14(3): 248.     CrossRef
  • Advances in external beam radiation for hepatocellular carcinoma, stereotactic body radiation therapy (SBRT) and particle therapy
    Lokesh Seth, Kevin L. Stephans
    Hepatoma Research.2024;[Epub]     CrossRef
  • Therapeutic Outcome of Stereotactic Body Radiotherapy for Small Hepatocellular Carcinoma Lesions – A Systematic Review and Network Meta-analysis
    L.-Q. Li, T.-S. Su, Q.-Y. Wu, Z.-T. Lin, S.-X. Liang
    Clinical Oncology.2023; 35(10): 652.     CrossRef
  • Post-operative recurrence of liver cancer according to antiviral therapy for detectable hepatitis B viremia: A nationwide study
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim
    European Journal of Internal Medicine.2023; 107: 66.     CrossRef
  • Stereotactic Body Radiotherapy for Hepatocellular Carcinoma: A Brief Overview
    Yukinori Matsuo
    Current Oncology.2023; 30(2): 2493.     CrossRef
  • Advances in Radiation Therapy for Primary Liver Cancer
    Kyle C. Cuneo, Daniel J. Herr
    Surgical Oncology Clinics of North America.2023; 32(3): 415.     CrossRef
  • 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

    Journal of Liver Cancer.2023; 23(1): 1.     CrossRef
  • Outcome of untreated low-level viremia versus antiviral therapy-induced or spontaneous undetectable HBV-DNA in compensated cirrhosis
    Daniel Q. Huang, Nobuharu Tamaki, Hyung Woong Lee, Soo Young Park, Yu Rim Lee, Hye Won Lee, Seng Gee Lim, Tae Seop Lim, Masayuki Kurosaki, Hiroyuki Marusawa, Toshie Mashiba, Masahiko Kondo, Yasushi Uchida, Haruhiko Kobashi, Koichiro Furuta, Namiki Izumi,
    Hepatology.2023; 77(5): 1746.     CrossRef
  • Stereotactic Body Radiation Therapy versus Surgical Resection for Stage I/II Hepatocellular Carcinoma
    Emrullah Birgin, Svetlana Hetjens, Moses Tam, Camilo Correa-Gallego, Nuh N. Rahbari
    Cancers.2023; 15(8): 2330.     CrossRef
  • Clinical impact of carbon‐ion radiotherapy on hepatocellular carcinoma with Child‐Pugh B cirrhosis
    Yuichi Hiroshima, Masaru Wakatsuki, Takashi Kaneko, Hirokazu Makishima, Naomi Nagatake Okada, Shigeo Yasuda, Hitoshi Ishikawa, Hiroshi Tsuji
    Cancer Medicine.2023; 12(13): 14004.     CrossRef
  • Local Therapies for Hepatocellular Carcinoma and Role of MRI-Guided Adaptive Radiation Therapy
    Yirong Liu, Brian Chou, Amulya Yalamanchili, Sara N. Lim, Laura A. Dawson, Tarita O. Thomas
    Journal of Clinical Medicine.2023; 12(10): 3517.     CrossRef
  • Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma in the era of chemo-diversity
    Hideki Iwamoto, Shigeo Shimose, Tomotake Shirono, Takashi Niizeki, Takumi Kawaguchi
    Clinical and Molecular Hepatology.2023; 29(3): 593.     CrossRef
  • Impact of radiation therapy and alpha-fetoprotein level on survival outcomes for patients with hepatocellular carcinoma: A population-based study
    Yahong Chen, Xueqing Yang, Xiawei Li
    Clinics and Research in Hepatology and Gastroenterology.2023; 47(8): 102196.     CrossRef
  • Loco-regional therapies competing with radiofrequency ablation in potential indications for hepatocellular carcinoma: a network meta-analysis
    Ha Il Kim, Jihyun An, Seungbong Han, Ju Hyun Shim
    Clinical and Molecular Hepatology.2023; 29(4): 1013.     CrossRef
  • Large hepatocellular carcinoma treated with sequential SBRT and immunotherapy with anti-VEGF (Vascular Endothelial Growth Factor) therapy
    Bardia Bidarmaghz, Marwan Idrees, Yoo Young Lee, Peter Hodgkinson
    BMJ Case Reports.2023; 16(12): e256931.     CrossRef
  • Episodic Detectable Viremia Does Not Affect Prognosis in Untreated Compensated Cirrhosis With Serum Hepatitis B Virus DNA <2,000 IU/mL
    Hye Won Lee, Soo Young Park, Yu Rim Lee, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    American Journal of Gastroenterology.2022; 117(2): 288.     CrossRef
  • Stereotactic body radiation therapy for primary liver tumors: An effective liver‐directed therapy in the toolbox
    Hannah J. Roberts, Jennifer Y. Wo
    Cancer.2022; 128(5): 956.     CrossRef
  • External Validation of the FSAC Model Using On-Therapy Changes in Noninvasive Fibrosis Markers in Patients with Chronic Hepatitis B: A Multicenter Study
    Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, In Kyung Min, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2022; 14(3): 711.     CrossRef
  • Stereotactic body radiation therapy as a salvage treatment for single viable hepatocellular carcinoma at the site of incomplete transarterial chemoembolization: a retrospective analysis of 302 patients
    Sumin Lee, Jinhong Jung, Jin-hong Park, So Yeon Kim, Jonggi Choi, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Hee Hyun Park, Jong Hoon Kim, Sang Min Yoon
    BMC Cancer.2022;[Epub]     CrossRef
  • Hypofractionation in Hepatocellular Carcinoma – The Effect of Fractionation Size
    S. Lewis, A. Barry, M.A. Hawkins
    Clinical Oncology.2022; 34(5): e195.     CrossRef
  • Stereotactic body radiation therapy for hepatocellular carcinoma: From infancy to ongoing maturity
    Shirley Lewis, Laura Dawson, Aisling Barry, Teodor Stanescu, Issa Mohamad, Ali Hosni
    JHEP Reports.2022; 4(8): 100498.     CrossRef
  • The role of stereotactic body radiotherapy in hepatocellular carcinoma: guidelines and evidences
    Yulin Hu, Caining Zhao, Ren Ji, Wenqi Chen, Qi Shen, CL Chiang, Jeff Chan, Lingyu Ma, Hongwei Yang, Tiffany Wong, Susannah Ellsworth, Chung-Mau Lo, Laura A. Dawson, Feng-Ming (Spring) Kong
    Journal of the National Cancer Center.2022; 2(3): 171.     CrossRef
  • Prognosis and Risk Factors of Recurrence in HBV-Related Small Hepatocellular Carcinoma After Stereotactic Body Radiation Therapy
    Yifan Han, Jianxiang Liu, Jiali Pan, Hongyu Chen, Ning Tan, Qian Kang, Yuqing Yang, Xiaoyuan Xu, Wengang Li
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • High rates of treatment stage migration for early hepatocellular carcinoma and association with adverse outcomes: An Australian multicenter study
    Kee Fong Loo, Richard J Woodman, Damjana Bogatic, Vidyaleha Chandran, Kate Muller, Mohamed Asif Chinnaratha, John Bate, Kirsty Campbell, Matthew Maddison, Sumudu Narayana, Hien Le, David Pryor, Alan Wigg
    JGH Open.2022; 6(9): 599.     CrossRef
  • Stereotactic body radiotherapy versus radiofrequency ablation as initial treatment of small hepatocellular carcinoma
    Hwang Sik Shin, Sae Hwan Lee, Baek Gyu Jun, Hong Soo Kim, Seong Hee Kang, Ji Young Park, Soo In Choi, Gab Jin Cheon, Young Don Kim, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim, Soung Won Jeong, Jae Young Jang, Ki Tae Suk, Dong Joon Kim, In Young Jo, Yong
    European Journal of Gastroenterology & Hepatology.2022; 34(11): 1187.     CrossRef
  • 2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

    Clinical and Molecular Hepatology.2022; 28(4): 583.     CrossRef
  • Prognostic Impact of MAFLD Following Surgical Resection of Hepatitis B Virus-Related Hepatocellular Carcinoma: A Nationwide Cohort Study
    Byungyoon Yun, Sang Hoon Ahn, Juyeon Oh, Jin-Ha Yoon, Beom Kyung Kim
    Cancers.2022; 14(20): 5002.     CrossRef
  • Stereotactic body radiation therapy for elderly patients with small hepatocellular carcinoma: a retrospective observational study
    Jeong Yun Jang, Jinhong Jung, Danbi Lee, Ju Hyun Shim, Kang Mo Kim, Young-Suk Lim, Han Chu Lee, Jin-hong Park, Sang Min Yoon
    Journal of Liver Cancer.2022; 22(2): 136.     CrossRef
  • 2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

    Korean Journal of Radiology.2022; 23(12): 1126.     CrossRef
  • Image-Guided Proton Therapy for Elderly Patients with Hepatocellular Carcinoma: High Local Control and Quality of Life Preservation
    Hiromitsu Iwata, Hiroyuki Ogino, Yukiko Hattori, Koichiro Nakajima, Kento Nomura, Kensuke Hayashi, Toshiyuki Toshito, Shigeru Sasaki, Shingo Hashimoto, Jun-etsu Mizoe, Yuta Shibamoto
    Cancers.2021; 13(2): 219.     CrossRef
  • A New Prognostic Model for Radiation-Based Hepatocellular Carcinoma Treatment
    Ting-Shi Su, Shi-Xiong Liang, Li-Qing Li, Qiu-Hua Liu, Xue-Zhang Duan, Jing Sun, Hai Zeng, Jian-Xu Li, Xiao-Fei Zhu, Hong-Qing Zhuang, Ping Liang
    SSRN Electronic Journal .2021;[Epub]     CrossRef
  • Metformin and Dichloroacetate Suppress Proliferation of Liver Cancer Cells by Inhibiting mTOR Complex 1
    Tae Suk Kim, Minjong Lee, Minji Park, Sae Yun Kim, Min Suk Shim, Chea Yeon Lee, Dae Hee Choi, Yuri Cho
    International Journal of Molecular Sciences.2021; 22(18): 10027.     CrossRef
  • External validation of CAGE‐B and SAGE‐B scores for Asian chronic hepatitis B patients with well‐controlled viremia by antivirals
    Jung Hyun Ji, Soo Young Park, Won Jeong Son, Hye Jung Shin, Hyein Lee, Hye Won Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Viral Hepatitis.2021; 28(6): 951.     CrossRef
  • Radiofrequency ablation versus stereotactic body radiation therapy for small (≤ 3 cm) hepatocellular carcinoma: A retrospective comparison analysis
    Yuri Jeong, Kyung Jin Lee, So Jung Lee, Yong Moon Shin, Min‐Ju Kim, Young‐Suk Lim, Han Chu Lee, Jinhong Jung, Jin‐hong Park, Jong Hoon Kim, So Yeon Kim, Sang Min Yoon
    Journal of Gastroenterology and Hepatology.2021; 36(7): 1962.     CrossRef
  • Updates on the Diagnosis and Management of Hepatocellular Carcinoma
    Muhammad Kamran, Aimun Raees, Wasim Jafri
    Euroasian Journal of Hepato-Gastroenterology.2021; 11(1): 32.     CrossRef
  • Optimal stereotactic body radiotherapy dosage for hepatocellular carcinoma: a multicenter study
    Ting-Shi Su, Qiu-Hua Liu, Xiao-Fei Zhu, Ping Liang, Shi-Xiong Liang, Lin Lai, Ying Zhou, Yong Huang, Tao Cheng, Le-Qun Li
    Radiation Oncology.2021;[Epub]     CrossRef
  • Effect of tenofovir alafenamide vs. tenofovir disoproxil fumarate on hepatocellular carcinoma risk in chronic hepatitis B
    Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park
    Journal of Viral Hepatitis.2021; 28(11): 1570.     CrossRef
  • Multi-Institutional Retrospective Study of Radiotherapy for Hepatocellular Carcinoma in the Caudate Lobe
    Sung Uk Lee, Sang Min Yoon, Jason Chia-Hsien Cheng, Tae Hyun Kim, Bo Hyun Kim, Jin-hong Park, Jinhong Jung, Chiao-Ling Tsai, Yun Chiang, Joong-Won Park
    Frontiers in Oncology.2021;[Epub]     CrossRef
  • Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma
    Sojung Han, Hye Jin Choi, Seung-Hoon Beom, Hye Rim Kim, Hyein Lee, Jae Seung Lee, Hye Won Lee, Jun Yong Park, Seung Up Kim, Do Young Kim, Sang Hoon Ahn, Kwang-Hyub Han, Jinsil Seong, Jong Yun Won, Beom Kyung Kim
    Journal of Cancer Research and Clinical Oncology.2021; 147(10): 3123.     CrossRef
  • The Prognostic Role of On-Treatment Liver Stiffness for Hepatocellular Carcinoma Development in Patients with Chronic Hepatitis B
    Hye Won Lee, Hyun Woong Lee, Jae Seung Lee, Yun Ho Roh, Hyein Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Journal of Hepatocellular Carcinoma.2021; Volume 8: 467.     CrossRef
  • Impact of tenofovir alafenamide vs. entecavir on hepatocellular carcinoma risk in patients with chronic hepatitis B
    Hye Won Lee, Young Youn Cho, Hyein Lee, Jae Seung Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim, Soo Young Park
    Hepatology International.2021; 15(5): 1083.     CrossRef
  • Stereotactic body radiotherapy vs radiofrequency ablation for the treatment of hepatocellular carcinoma: a meta-analysis
    Antonio Facciorusso, Andrea Chierici, Ivan Cincione, Rodolfo Sacco, Daryl Ramai, Babu P Mohan, Saurabh Chandan, Andrew Ofosu, Christian Cotsoglou
    Expert Review of Anticancer Therapy.2021; 21(6): 681.     CrossRef
  • Novel Liver Stiffness-Based Nomogram for Predicting Hepatocellular Carcinoma Risk in Patients with Chronic Hepatitis B Virus Infection Initiating Antiviral Therapy
    Jae Seung Lee, Hyun Woong Lee, Tae Seop Lim, Hye Jung Shin, Hye Won Lee, Seung Up Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Beom Kyung Kim
    Cancers.2021; 13(23): 5892.     CrossRef
  • In reply to Huo et al.: Treating small hepatocellular carcinoma: Stereotactic body radiation therapy versus radiofrequency ablation
    S Park, J Jung, B Cho, SY Kim, S‐C Yun, Y‐S Lim, HC Lee, J Park, J‐h Park, JH Kim, SM Yoon
    Journal of Gastroenterology and Hepatology.2020; 35(12): 2293.     CrossRef
  • 11,846 View
  • 228 Download
  • 62 Web of Science
  • Crossref
The retrospective cohort study for survival rate in patients with advanced hepatocellular carcinoma receiving radiotherapy or palliative care
Hyuk Soo Eun, Min Jung Kim, Hye Jin Kim, Kwang Hun Ko, Hee Seok Moon, Eaum Seok Lee, Seok Hyun Kim, Heon Young Lee, Byung Seok Lee
Korean J Hepatol 2011;17(3):189-198.
Published online September 30, 2011
DOI: https://doi.org/10.3350/kjhep.2011.17.3.189
Background/Aims

This study was conducted to investigate the assessment of treatment efficacy of radiotherapy (RT) and other therapeutic modalities compared with palliative care only for treatment with advanced hepatocellular carcinoma (HCC).

Methods

From 2002 to 2010, based on the case of 47 patients with advanced HCC, we have investigated each patients' Child-Pugh's class, ECOG performance, serum level of alpha fetoprotein and other baseline characteristics that is considered to be predictive variables and values for prognosis of HCC. Out of overall patients, the 29 patients who had received RT were selected for one group and the 18 patients who had received only palliative care were classified for the other. The analysis in survival between the two groups was done to investigate the efficacy of RT.

Results

Under the analysis in survival, the mean survival time of total patients group was revealed between 30.1 months and 45.9 months in RT group, while it was 4.8 months in palliative care group, respectively. In the univariate analysis for overall patients, there were significant factors which affected survival rate like as follows: ECOG performance, Child-Pugh's class, the tumor size, the type of tumor, alpha fetoprotein, transarterial chemoembolization, and RT. The regressive analysis in multivariate Cox for total patients. No treatment under radiotherapy and high level of Child-Pugh's class grade were independent predictors of worse overall survival rate in patients. In contrast, for the subset analysis of the twenty-nine patients treated with radiotherapy, the higher serum level of alpha fetoprotein was an independent predictors of worse overall survival rate in patients.

Conclusions

We found that the survival of patients with advanced HCC was better with radiotherapy than with palliative care. Therefore, radiotherapy could be a good option for in patients with advanced HCC.

Citations

Citations to this article as recorded by  Crossref logo
  • Characteristics and survival of advanced untreated hepatocellular carcinoma of non-viral etiology
    Senarath Pathiranage Nimasha Ekanayaka, Nathasha Luke, Suchintha Bandara Thilakarathne, Anuradha Dassanayake, Mahiman Bhaagya Gunetilleke, Madunil A. Niriella, Rohan Chaminda Siriwardana
    Indian Journal of Gastroenterology.2024; 43(6): 1176.     CrossRef
  • Galactose Derivative-Modified Nanoparticles for Efficient siRNA Delivery to Hepatocellular Carcinoma
    Kuan-Wei Huang, Yu-Tsung Lai, Guann-Jen Chern, Shao-Feng Huang, Chia-Lung Tsai, Yun-Chieh Sung, Cheng-Chin Chiang, Pi-Bei Hwang, Ting-Lun Ho, Rui-Lin Huang, Ting-Yun Shiue, Yunching Chen, Sheng-Kai Wang
    Biomacromolecules.2018; 19(6): 2330.     CrossRef
  • Radiotherapy as valid modality for hepatocellular carcinoma with portal vein tumor thrombosis
    Jeong Il Yu, Hee Chul Park
    World Journal of Gastroenterology.2016; 22(30): 6851.     CrossRef
  • 2014 Korean Liver Cancer Study Group-National Cancer Center Korea Practice Guideline for the Management of Hepatocellular Carcinoma

    Korean Journal of Radiology.2015; 16(3): 465.     CrossRef
  • Hepatocellular carcinoma: Surgeon's view on latest findings and future perspectives
    Jan Erik Slotta
    World Journal of Hepatology.2015; 7(9): 1168.     CrossRef
  • Considerations for Radiation Therapy in Hepatocellular Carcinoma: The Radiation Oncologists' Perspective
    Jeong Il Yu, Hee Chul Park
    Digestive Diseases.2014; 32(6): 755.     CrossRef
  • 9,672 View
  • 73 Download
  • Crossref
Clinical features and prognosis of primary biliary cirrhosis in Korea
Kyung-Ah Kim, M.D.1, Sook-Hyang Jeong, M.D.2, Jung Il Lee, M.D.3, Jong Eun Yeon, M.D.4, Heon Ju Lee, M.D.5, So Young Kwon, M.D.6, U Im Chang, M.D.7, Hyun Ju Min, M.D.8
Korean J Hepatol 2010;16(2):139-146.
Published online June 25, 2010
DOI: https://doi.org/10.3350/kjhep.2010.16.2.139
Background/Aims
This study investigated the clinical features and prognosis of primary biliary cirrhosis (PBC) in Korea. Methods: Clinical data of patients diagnosed as PBC between 1997 and 2008 at eight referral hospitals were analyzed retrospectively. PBC was diagnosed based on liver function tests, presence of serum antimitochondrial antibody (AMA), and histopathological findings. Results: In total, 251 patients (218 females, 33 males, mean age 54 years) were enrolled, and the mean follow-up duration was 33.5 months. At the diagnosis, 61% of the patients were asymptomatic, 12% had decompensated liver cirrhosis, and 98% were positive for AMA. The serum alkaline phosphate (AlP) level was 2.6 times the upper limit of normal, aspartate aminotransferase was 105 U/l, and bilirubin was 2.0 mg/dl. The mean Mayo risk score was 5.5, and the Child-Pugh class was A, B, and C in 79%, 19%, and 2% of the patients, respectively. Ursodeoxycholic acid (UDCA) was used for treatment in 88% of the patients, among which 70% exhibited biochemical responses defined as normalization or a >40% decrease in AlP at 6 months. Eight deaths occurred during the follow-up, the causes were variceal bleeding, hepatic failure, and sepsis. The overall 5-year survival rate was 95%. The poor prognostic factors were being older than 60 years, high bilirubin, low albumin, ascites, high Mayo risk score, Child-Pugh class C, and initial presence of hepatic decompensation. Conclusions: Most patients diagnosed as PBC were asymptomatic, and these patients had a favorable short-term prognosis. The prognosis of PBC was dependent on the initial severity of liver disease.

Citations

Citations to this article as recorded by  Crossref logo
  • Clinical Characteristics and Prognosis of Concomitant Primary Biliary Cholangitis and Autoimmune Diseases: A Retrospective Study
    Yuwei Liu, Kai Han, Chen Liu, Fangfang Duan, Jun Cheng, Song Yang, Alessandro Granito
    Canadian Journal of Gastroenterology and Hepatology.2021;[Epub]     CrossRef
  • Current epidemiology and clinical characteristics of autoimmune liver diseases in South Korea
    Sook-Hyang Jeong
    Clinical and Molecular Hepatology.2018; 24(1): 10.     CrossRef
  • Clinical Features and Response to UDCA Treatment of Primary Biliary Cirrhosis
    Joo Young Kim, Tae Hun Kim, Kwon Yoo, Ye Ji Han, Jeong Eun Choi, Ji Yoon Kim, Min-Sun Cho
    The Ewha Medical Journal.2015; 38(3): 106.     CrossRef
  • Primary biliary cirrhosis: Clinical and laboratory criteria for its diagnosis
    Vasiliy Ivanovich Reshetnyak
    World Journal of Gastroenterology.2015; 21(25): 7683.     CrossRef
  • The Clinical Significance of Simplified Scoring Criteria as a Diagnostic Tool for Overlap Syndrome in Korea
    Min Suk Kim, Young Seok Kim, Sang Gyune Kim, Jin Myung Byun, La Young Yoon, Dong Hoon Han, Jong Joo Moon, Jae-Hyung Nam, Tae-Jin Kim, Sae Hwan Lee, Seung Won Jung, Hong Soo Kim, Boo sung Kim, Hee Kyung Kim
    Korean Journal of Medicine.2013; 84(2): 211.     CrossRef
  • Management of Primary Biliary Cirrhosis
    Kyung-Ah Kim
    Korean Journal of Medicine.2012; 82(1): 32.     CrossRef
  • Beneficial effects of candesartan, an angiotensin‐blocking agent, on compensated alcoholic liver fibrosis ‐ A randomized open‐label controlled study
    Moon Young Kim, Mee Yon Cho, Soon Koo Baik, Phil Ho Jeong, Ki Tae Suk, Yoon Ok Jang, Chang Jin Yea, Jae Woo Kim, Hyun Soo Kim, Sang Ok Kwon, Byung Su Yoo, Jang Young Kim, Min Seob Eom, Seung Hwan Cha, Sei Jin Chang
    Liver International.2012; 32(6): 977.     CrossRef
  • Prognostic indicators in primary biliary cirrhosis: significance of revised IAHG (International Autoimmune Hepatitis Group) score
    Ho Eun Jung, Jae Young Jang, Soung Won Jeong, Jin Nyoung Kim, Hee Yoon Jang, Yun Ju Cho, Sung Ae Woo, Sae Hwan Lee, Sang Gyune Kim, Sang-Woo Cha, Young Seok Kim, Young Deok Cho, Hong Soo Kim, Boo Sung Kim
    Clinical and Molecular Hepatology.2012; 18(4): 375.     CrossRef
  • The diagnosis and treatment of primary biliary cirrhosis
    Kyung-Ah Kim, Sook-Hyang Jeong
    The Korean Journal of Hepatology.2011; 17(3): 173.     CrossRef
  • Prognosis of Korean patients with primary biliary cirrhosis
    Byung-Cheol Song
    The Korean Journal of Hepatology.2010; 16(2): 109.     CrossRef
  • 7,452 View
  • 95 Download
  • Crossref
Prognostic Factors Affecting Survival Rate in Patients with Hepatocellular Carcinoma Treated by Transcatheter Chemoembolization
Sung Woo Kim,Soong hwan Lee,Byung Joo Roh,Jong Cheol Kim,Sung Soo Park,Dong Hoo Lee
Korean J Hepatol 2000;6(3):311-320.
Purpose
There have been studies concerning prognostic factors in patients with hepatocellular carcinoma (HCC) undergoing transcatheter arterial chemoembolization (TACE) but they reported different prognostic factors from each other. The aim of this study is to determine which prognostic factors contribute to long-term survival after TACE of hepatocellular carcinoma. Material and Method: Two hundred and forty-one patients with HCC who had been treated by TACE were analyzed retrospectively. TACE was accomplished by hepatic arterial infusion of a suspension of lipodol and anticancer drugs (Mitomycin-C and Adriamycin), either alone or followed by gelfoam embolization. Results: Male to female ratio was 4.7:1. Mean survival was 13.98 months. Maximum survival was 101 months. The overall cumulative survival rates at the end of the first and second years were, respectively, 41.54% and 20.06%. According to univariate analysis (log-rank scale test), variables significantly associated with survival were: sex, liver cirrhosis, Child-Pugh classification, gross type of the tumor, location of the tumor, size of the tumor, TNM stage, metastasis, portal vein thrombosis, arterioportal shunt, ascites, AFP, protein, albumin, alkaline phosphatase, AST, AST/ALT ratio, total bilirubin, and sodium. Multivariate analysis (Cox proportional hazard model) for the significant variables in a univarariate analysis revealed that the gross type of the tumor, portal vein thrombosis, and Child-Pugh classification were statistically significant independent prognostic factors. Conclusion: The prognosis of patients with HCC treated with TACE was affected favorably by the nodular type tumor, the patent main and the first-order portal vein, and the good liver function (Child-Pugh class A).
  • 3,372 View
  • 25 Download
Background
/Aim: Although hepatocellular carcinoma(HCC) shows poor prognosis, transcatheter hepatic arterial chemoembolization(TACE) can improve survival rate in some patient groups. This study investigated the synergy effect of the different clinical indices on the survival time in patients with HCC underwent TACE. Materials and Methods: A retrospective study of 241 patients with HCC who underwent TACE with a mixture of lipiodol, mitomycin-C and driamycin, alone or followed by gelfoam was conducted. Three different survival groups (A, less than 6 months; B, between between 6 and 23 months; and C, over 24 months) were compared. Results: Alkaline phosphatase was lowest in group C(p=0.0001). The longer the survival, the lower (p=0.027, p=0.007) the AST and AST/ALT ratio were. Albumin was higher (p=0.032), GGT and LDH were lower (p=0.003, p=0.002) in the long-term survival group. The long-term survival group revealed an absence of both ascites(p<0.002) and portal vein thrombosis(p<0.001), and lower TNM stage (P<0.0001). The single nodular type of HCC was more frequent (P<0.0001) and the size of tumor was smaller in the long-term survival group (P<0.0001). Child-Pugh class was lower in the long-term survival group (p=0.017). The higher serum albumin and elder age, the higher albumin and the lower alkaline phosphatase or alpha-fetoprotein, represented synergic effects on a long term survival. The higher albumin and the smaller size or the lower tumor stage, the higher albumin and platelet revealed similar synergy effects. Although the age or platelet is high, low albumin showed poor prognosis. Conclusion: Patients with small-sized single, nodular HCC in a low Child-Pugh class without evidence of ascites and portal vein thrombosis, and the higher level of serum albumin but lower levels of alpha-fetoprotein, alkaline phosphatase, GGT, and LDH, can expect a long-term survival over 24 months by the treatment of TACE. There are meaningful synergies of the different clinical variables affecting the survival times in the patients with HCC undergoing TACE.(Korean J Hepatol 2002;8:189-200)
  • 3,111 View
  • 34 Download